Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction A Cohort Study

被引:36
作者
Booth, John N., III [1 ]
Colantonio, Lisandro D. [1 ]
Chen, Ligong [1 ]
Rosenson, Robert S. [4 ]
Monda, Keri L. [5 ]
Safford, Monika M. [7 ]
Kilgore, Meredith L. [2 ]
Brown, Todd M. [3 ]
Taylor, Benjamin [5 ]
Dent, Ricardo [6 ]
Muntner, Paul [1 ]
Levitan, Emily B. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Epidemiol, 1700 Univ Blvd,LHL 452, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[4] Mt Sinai Icahn Sch Med, Dept Med, New York, NY USA
[5] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA
[6] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
[7] Weill Cornell Med, Dept Med, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2017年 / 10卷 / 10期
关键词
Medicare; myocardial infarction; secondary prevention; statins; CORONARY-HEART-DISEASE; SECONDARY PREVENTION; THERAPY; CARE; ATORVASTATIN; ADHERENCE; DYNAMICS; CLAIMS; RATES;
D O I
10.1161/CIRCOUTCOMES.117.003626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although the benefits of statins accrue over time, treatment discontinuation is common. Examining the patterns of statin discontinuation, reinitiation, and persistence after reinitiation among Medicare beneficiaries after hospital discharge for a myocardial infarction may help increase statin use in high-risk patients. Methods and Results-Medicare beneficiaries with a statin fill claim within 30 days after hospital discharge for myocardial infarction in 2007 to 2012 (n = 158 795) were followed for 182 days post-discharge to identify discontinuation, defined as 60 continuous days without statins available. Reinitiation, defined by a statin fill, was identified in the 365 days post-discontinuation. High persistence was defined as proportion of days covered >= 80% with >= 1 day of statin supply 182 days after reinitiation. Follow-up ended on December 31, 2014. In the 182 days after myocardial infarction hospital discharge, 15.4% of beneficiaries discontinued statins. Of this group, 53.7% reinitiated statins. On reinitiation, 27.1% changed statin type, 6.9% up-titrated intensity, 14.4% down-titrated intensity, and 66.0% had the same statin and intensity. In the 182 days after reinitiation, 45.8% had high persistence. Moderate-and high-versus low-intensity statins were associated with a lower risk for statin discontinuation (moderate intensity: relative risk [RR], 0.93; 95% confidence interval [CI], 0.89-0.96; high-intensity: RR, 0.95; 95% CI, 0.91-0.99). High persistence was less common after reinitiating high-versus low-intensity statins (RR, 0.80; 95% CI, 0.75-0.86), but no association was present for those reinitiating a moderate-versus low-intensity statin (RR, 0.95; 95% CI, 0.90-1.01). Down-titrating versus reinitiating the same statin intensity (RR, 1.10; 95% CI, 1.05-1.16) and reinitiating a different versus the same statin (RR, 1.10; 95% CI, 1.06-1.14) were associated with high persistence after treatment reinitiation. Conclusions-Although many people who discontinue a statin reinitiate treatment, statin persistence after reinitiation was low. Reinitiating therapy with moderate-intensity statins, down-titration, and using a different statin may promote persistence.
引用
收藏
页数:31
相关论文
共 28 条
  • [1] Long-term persistence in use of statin therapy in elderly patients
    Benner, JS
    Glynn, RJ
    Mogun, H
    Neumann, PJ
    Weinstein, MC
    Avorn, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04): : 455 - 461
  • [2] Physician follow-up and provider continuity are associated with long-term medication adherence - A study of the dynamics of statin use
    Brookhart, M. Alan
    Patrick, Amanda R.
    Schneeweiss, Sebastian
    Avorn, Jerry
    Dormuth, Colin
    Shrank, William
    van Wijk, Boris L. G.
    Cadarette, Suzanne M.
    Canning, Claire F.
    Solomon, Daniel H.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (08) : 847 - 852
  • [3] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [4] Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Cannon, CP
    Braunwald, E
    McCabe, CH
    Rader, DJ
    Rouleau, JL
    Belder, R
    Joyal, SV
    Hill, KA
    Pfeffer, MA
    Skene, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1495 - 1504
  • [5] Compliance with a statin treatment in a usual-care setting: Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia
    Caspard, H
    Chan, AK
    Walker, AM
    [J]. CLINICAL THERAPEUTICS, 2005, 27 (10) : 1639 - 1646
  • [6] Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data
    Colantonio, Lisandro D.
    Kent, Shia T.
    Huang, Lei
    Chen, Ligong
    Monda, Keri L.
    Serban, Maria-Corina
    Manthripragada, Angelika
    Kilgore, Meredith L.
    Rosenson, Robert S.
    Muntner, Paul
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) : 525 - 533
  • [7] Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use
    Colantonio, Lisandro D.
    Kent, Shia T.
    Kilgore, Meredith L.
    Delzell, Elizabeth
    Curtis, Jeffrey R.
    Howard, George
    Safford, Monika M.
    Muntner, Paul
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (07) : 827 - 835
  • [8] Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
    De Vera, Mary A.
    Bhole, Vidula
    Burns, Lindsay C.
    Lacaille, Diane
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) : 684 - 698
  • [9] Suboptimal statin adherence and discontinuation in primary and secondary prevention populations - Should we target patients with the most to gain?
    Ellis, JJ
    Erickson, SR
    Stevenson, JG
    Bernstein, SJ
    Stiles, RA
    Fendrick, AM
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 (06) : 638 - 645
  • [10] A systematic review of statin-induced muscle problems in clinical trials
    Ganga, Harsha V.
    Slim, Hanna B.
    Thompson, Paul D.
    [J]. AMERICAN HEART JOURNAL, 2014, 168 (01) : 6 - 15